These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24846067)

  • 41. Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma.
    Bi C; Chung TH; Huang G; Zhou J; Yan J; Ahmann GJ; Fonseca R; Chng WJ
    Oncotarget; 2015 Sep; 6(28):26508-18. PubMed ID: 26164366
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of miRNAs in plasma cell dyscrasias.
    Glavey S; Manier S; Sacco A; Rossi G; Ghobrial IM; Roccaro AM
    Microrna; 2014; 2(3):165-73. PubMed ID: 25069440
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma.
    Soliman AM; Lin TS; Mahakkanukrauh P; Das S
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066062
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting miRNAs by polyphenols: Novel therapeutic strategy for cancer.
    Pandima Devi K; Rajavel T; Daglia M; Nabavi SF; Bishayee A; Nabavi SM
    Semin Cancer Biol; 2017 Oct; 46():146-157. PubMed ID: 28185862
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance.
    Desantis V; Saltarella I; Lamanuzzi A; Melaccio A; Solimando AG; Mariggiò MA; Racanelli V; Paradiso A; Vacca A; Frassanito MA
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349317
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Aberrant micro RNA and epigenetic network are associated with progression from MGUS to multiple myeloma].
    Handa H
    Rinsho Ketsueki; 2015 Aug; 56(8):981-8. PubMed ID: 26345556
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of micro-RNAs in drug resistance of multiple myeloma.
    Abdi J; Jian H; Chang H
    Oncotarget; 2016 Sep; 7(37):60723-60735. PubMed ID: 27494872
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epigenetics in Multiple Myeloma.
    Glavey SV; Manier S; Sacco A; Salem K; Kawano Y; Bouyssou J; Ghobrial IM; Roccaro AM
    Cancer Treat Res; 2016; 169():35-49. PubMed ID: 27696257
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation.
    Amodio N; D'Aquila P; Passarino G; Tassone P; Bellizzi D
    Expert Opin Ther Targets; 2017 Jan; 21(1):91-101. PubMed ID: 27892767
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Circulating MicroRNAs in Multiple Myeloma: a Literature Review.
    Tiruneh T; Melku M
    Clin Lab; 2020 Dec; 66(12):. PubMed ID: 33337835
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MicroRNAs in multiple myeloma and related bone disease.
    Rossi M; Tagliaferri P; Tassone P
    Ann Transl Med; 2015 Dec; 3(21):334. PubMed ID: 26734644
    [TBL] [Abstract][Full Text] [Related]  

  • 52. miR-186 inhibits cell proliferation in multiple myeloma by repressing Jagged1.
    Liu Z; Zhang G; Yu W; Gao N; Peng J
    Biochem Biophys Res Commun; 2016 Jan; 469(3):692-7. PubMed ID: 26679605
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Promises and challenges of MicroRNA-based treatment of multiple myeloma.
    Tagliaferri P; Rossi M; Di Martino MT; Amodio N; Leone E; Gulla A; Neri A; Tassone P
    Curr Cancer Drug Targets; 2012 Sep; 12(7):838-46. PubMed ID: 22671926
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling.
    Tang B; Xu A; Xu J; Huang H; Chen L; Su Y; Zhang L; Li J; Fan F; Deng J; Tang L; Sun C; Hu Y
    Int J Cancer; 2018 Jan; 142(1):109-120. PubMed ID: 28905994
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma.
    Amodio N; Di Martino MT; Neri A; Tagliaferri P; Tassone P
    Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S125-37. PubMed ID: 23692413
    [TBL] [Abstract][Full Text] [Related]  

  • 56. GPER1 Activation Exerts Anti-Tumor Activity in Multiple Myeloma.
    Gallo Cantafio ME; Torcasio R; Scionti F; Mesuraca M; Ronchetti D; Pistoni M; Bellizzi D; Passarino G; Morelli E; Neri A; Viglietto G; Amodio N
    Cells; 2023 Sep; 12(18):. PubMed ID: 37759449
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications.
    Puła A; Robak P; Mikulski D; Robak T
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769503
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical significance of circulatory microRNA-203 in serum as novel potential diagnostic marker for multiple myeloma.
    Gupta N; Kumar R; Seth T; Garg B; Sati HC; Sharma A
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1601-1611. PubMed ID: 30891618
    [TBL] [Abstract][Full Text] [Related]  

  • 59. EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells.
    La Rocca F; Airoldi I; Di Carlo E; Marotta P; Falco G; Simeon V; Laurenzana I; Trino S; De Luca L; Todoerti K; Villani O; Lackmann M; D'Auria F; Frassoni F; Neri A; Del Vecchio L; Musto P; Cilloni D; Caivano A
    Cell Oncol (Dordr); 2017 Oct; 40(5):483-496. PubMed ID: 28721629
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MicroRNA-19a functions as an oncogene by regulating PTEN/AKT/pAKT pathway in myeloma.
    Zhang X; Chen Y; Zhao P; Zang L; Zhang Z; Wang X
    Leuk Lymphoma; 2017 Apr; 58(4):932-940. PubMed ID: 27830963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.